摘要
目的系统评价FIB-4预测慢性肝病患者出现肝细胞癌的价值。方法检索PubMed、Web of Science、中国知网和万方数据库中有关FIB-4预测慢性肝病患者肝细胞癌风险的文献,并根据纳入和排除标准筛选,利用RevMan 5.3软件进行统计分析。结果共纳入文献35篇,包含肝细胞癌患者94569例。Meta分析结果显示:慢性肝病患者基线高FIB-4(HR=1.57,95%CI:1.41-1.75,P<0.01)及抗病毒治疗后高FIB-4(HR=2.40,95%CI:1.74-3.32,P<0.01)与慢性乙肝或慢性丙肝患者的高肝细胞癌风险有关。结论FIB-4可预测慢性肝病患者的肝细胞癌风险。
Objective To systematically evaluate the value of fibrosis-4(FIB-4)in predicting future hepatocellular carcinoma(HCC)in patients with chronic liver disease(CLD).Methods We searched PubMed,Web of Science,Wan-fang and CNKI databases for relevant literatures of FIB-4 predicting HCC risk in CLD patients,and selected eligible literatures according to the including and excluding criteria.Revman 5.3 software was used to perform statistical analyses.Results A total of 35 articles with 94,569 CLD patients were included.Meta-analysis results showed that high baseline FIB-4 predicted high HCC risk in CLD patients(HR=1.57,95%CI:1.41-1.75,P<0.01).Post-treatment high FIB-4(HR=2.40,95%CI:1.74-3.32,P<0.01)was associated with high risk of future HCC in patients with chronic hepatitis B or hepatitis C virus.Conclusion FIB-4 is useful in predicting future HCC in CLD patients.
作者
贺超
黄邵斌
He Chao;Huang Shaobin(Department of General Surgery,Changsha Central Hospital,University of South China,Changsha 410018,China)
出处
《临床荟萃》
CAS
2022年第9期779-784,共6页
Clinical Focus
